Tirzepatide 30mg

What is Tirzepatide (30 mg)?

Tirzepatide (30 mg) is a synthetic peptide developed for advanced metabolic and endocrine research. It functions as a dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-receptor interaction profile makes it an essential research tool for studying integrated hormonal signaling pathways involved in energy metabolism and glucose signaling pathways.

The peptide incorporates specific amino acid substitutions and a fatty acid (C20) side-chain modification. These structural adaptations enhance molecular stability and allow for prolonged receptor engagement in laboratory models, making it suitable for studying sustained intracellular signaling compared to shorter-acting incretin analogs.

Product Specifications

• Synonyms: LY3298176, P1206, tirzepatida, tirzepatidum
• CAS Number: 2023788-19-2
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight:48 g/mol
• Peptide Sequence:
  Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 30 mg lyophilized powder in a sealed research-grade vial
• Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Tirzepatide (30 mg)

• Synthetic peptide designed for dual receptor-targeted metabolic signaling research
• Targets both GIP and GLP-1 receptors in experimental systems
• Fatty acid (C20) side-chain modification enhances stability and allows prolonged receptor interaction
• High analytical purity confirmed by HPLC and mass spectrometry
• Supplied as a lyophilized powder to preserve structural integrity prior to reconstitution
• Suitable for in vitro and preclinical metabolic research models
• Engineered for reproducibility and batch consistency across studies

How Tirzepatide (30 mg) Supports Research

Tirzepatide (30 mg) is used in laboratory research to investigate the coordinated signaling of GIP and GLP-1 receptors. By targeting both receptor pathways, this peptide allows researchers to examine how dual agonist activity influences intracellular signaling cascades, glucose signaling pathways, and metabolic pathway integration.

In experimental models, researchers study receptor binding dynamics, cyclic adenosine monophosphate (cAMP) activation, downstream signaling, and time-dependent metabolic responses. Its structural stability enables the evaluation of prolonged receptor engagement and comparison with single-pathway incretin analogs.

Research Applications & Usage Information

Tirzepatide (30 mg) is commonly used in laboratory research for:

• Dual incretin receptor signaling studies (GIP and GLP-1)
• Glucose metabolism and endocrine communication models
• Energy balance and metabolic regulation research
• Cellular signal transduction and second-messenger pathway analysis
• Comparative studies of long-acting peptide analogs
• Preclinical metabolic disorder models
• Hormone–receptor interaction investigations

All uses are investigational and restricted to controlled laboratory research environments.

Handling and Storage Recommendations

• Store at 2–8 °C (≤–20 °C for long-term storage). Protect from light exposure.
• Keep the vial sealed and protected from moisture until reconstitution.
• Allow the vial to equilibrate before opening to minimize exposure to condensation.
• After reconstitution, store solutions at 2–8 °C according to laboratory protocol.
• Avoid repeated freeze-thaw cycles to support research applications.
• Follow sterile laboratory procedures during preparation and handling.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
2. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5
3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009